Objectively measure speech in Parkinson’s disease patients with great precision

In 2020, an estimated 9.4 million people globally were living with Parkinson’s disease, with numbers increasing to 12.7 million people by 2027. Coupled with the subjective nature of current Parkinson’s disease monitoring assessment methods, there is a need for sensitive, scalable and meaningful assessments of disease monitoring. Redenlab is a world leader in the development of speech data capture and analysis tools, creating objective motor speech and cognitive-linguistic -based assessments. Their approach has proven utility in industry and academic driven studies, enhancing decision making at each stage of the drug development and evaluation process.

ParkinSong: a clinical trial turn PD treatment

Working with scientists from the Conservatorium of Music at The University of Melbourne in Australia, Redenlab assisted in outcome measure design and analysis for a randomized trial of ParkinSong, a group therapy session for people with Parkinson’s disease.

Since it’s clinical trial, the therapy has been employed across Australia by Parkinson’s Australia, an Australian advocacy group dedicated to improving the quality of life of people diagnosed with Parkinson’s disease.

Redenlab Parkinson’s Disease experience

box-icon

Sites

30

box-icon

Patients

200

box-icon

Clinical trials

4

box-icon

Natural history studies

3

Latest news and updates

  • Posted on 17 November, 2022
    The 4th Annual Kabuki Syndrome Foundation Research Conference to be held virtually on Friday, November 4, 2022. The Annual Conference is the hallmark event for the community, and largest fundraising event that supports Kabuki syndrome...
    • Posted on 21 October, 2022
      Join World BI and Redenlab for the 20th Clinical Trials Innovation Programme, to learn from experts in the drug development industry. Hear from CEO Dr Adam Vogel and other leading industry experts exploring the future...